多肽聚合纳米药物在肿瘤靶向治疗中的研究进展

张莹瑄; 陈文莉; 陈红宇; 畅立圣; 杨柳

doi:10.16306/j.1008-861x.2022.S1.059

您当前的位置：

首页 >

文章列表页 >

多肽聚合纳米药物在肿瘤靶向治疗中的研究进展

综　　述 | 更新时间：2022-08-29

- 多肽聚合纳米药物在肿瘤靶向治疗中的研究进展
- Research progress of polypeptide polymerized nanodrugs in tumor targeted therapy
- 上海中医药大学学报 2022年36卷第S1期页码：291-295
- 作者机构：
  
  1.上海中医药大学附属曙光医院宝山分院肿瘤一科（上海　201999）
- 作者简介：
  
  张莹瑄，女，硕士，医师，主要从事中西医结合防治消化道肿瘤的临床及基础研究
  杨柳，副主任医师；E-mail：bsyykyc@shutcm.edu.cn
- 基金信息：
  
  国家自然科学基金资助项目(81904013);中国博士后科学基金资助项目(2021M700548);上海市自然科学基金项目(19zr143800);上海市科委中医引导类项目(19401933100);上海市科委医学创新研究专项项目(21Y11922200);上海中医药大学附属曙光医院宝山分院国家自然科学基金培育项目(GZRPY-201801)
- DOI：10.16306/j.1008-861x.2022.S1.059
  中图分类号：
扫描看全文
张莹瑄,陈文莉,陈红宇等.多肽聚合纳米药物在肿瘤靶向治疗中的研究进展[J].上海中医药大学学报,2022,36(S1):291-295.

ZHANG Yingxuan,CHEN Wenli,CHEN Hongyu,et al.Research progress of polypeptide polymerized nanodrugs in tumor targeted therapy[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(S1):291-295.
张莹瑄,陈文莉,陈红宇等.多肽聚合纳米药物在肿瘤靶向治疗中的研究进展[J].上海中医药大学学报,2022,36(S1):291-295. DOI： 10.16306/j.1008-861x.2022.S1.059.

ZHANG Yingxuan,CHEN Wenli,CHEN Hongyu,et al.Research progress of polypeptide polymerized nanodrugs in tumor targeted therapy[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(S1):291-295. DOI： 10.16306/j.1008-861x.2022.S1.059.

摘要

肿瘤组织由于肿瘤微环境、生物屏障等特点，化疗、免疫、中药等药物难以靶向渗透破坏肿瘤遗传物质。多肽聚合纳米药物具有易组装、可降解、靶向性等特点，由多肽聚合纳米药物介导的递送系统已成为肿瘤靶向性释药的主要研究方向。通过概述了近年来多肽纳米药物利用纳米药物递送系统多靶点结合、响应，对肿瘤靶向性释放，提高化疗、免疫、中药等抗肿瘤药物精准渗透疗效，降低口服吸收难溶性及毒副反应的研究进展，该领域也将成为未来抗肿瘤药物研究的主要发展方向。

Abstract

Due to the characteristics of tumor microenvironment and biological barrier， chemotherapy， immunity， traditional Chinese medicine and other drugs are difficult to penetrate and destroy tumor genetic material. Polypeptide polymerized nanodrugs have the characteristics of easy assembly， degradability and targeting， and the delivery system mediated by polypeptide polymerized nanodrugs has become the main research direction of tumor targeted drug release. This paper summarizes the recent progress of polypeptide nanodrugs that use multi-target combination and response of nanodrug delivery system， to tumor targeted release， improve the precise penetration curative efficacy of anti-tumor drugs such as chemotherapy， immunity and traditional Chinese medicine， and reduce oral absorption insoluble， toxic and side effects. This field will also become the main development direction of antitumor drug research in the future.

关键词

纳米颗粒多肽纳米药物递送系统肿瘤靶向治疗

Keywords

nanoparticlespolypeptidenanodrug delivery systemtumortargeted therapy

references

KUMAR R， SHIN W S， SUNWOO K， et al. Small conjugate-based theranostic agents： an encouraging approach for cancer therapy［J］. Chem Soc Rev， 2015， 44（19）： 6670-6683.

DREIFUSS T， BETZER O， SHILO M， et al. A challenge for theranostics： is the optimal particle for therapy also optimal for diagnostics？［J］. Nanoscale， 2015， 7（37）： 15175-15184.

ZHU H J， FANG Y， MIAO Q Q， et al. Regulating near-infrared photodynamic properties of semiconducting polymer nanotheranostics for optimized cancer therapy［J］. ACS Nano， 2017， 11（9）： 8998-9009.

SNEIDER A， DYKE D V， PALIWAL S，et al. Remotely triggered nano-theranostics for cancer applications［J］. Nanotheranostics， 2017， 1（1）： 1-22.

HOFMANN S， BELLMANN-SICKERT K， BECK-SICKINGER A G. Chemical modification of neuropeptide Y for human Y1 receptor targeting in health and disease［J］. Biol Chem， 2019， 400（3）： 299-311.

VEGGIANI G， SIDHU S S. Peptides meet ubiquitin： Simple interactions regulating complex cell signaling［J］. Peptide Science， 2018， 111（1）： e24091.

GHADIRI M R，GRANJA J R，MILLIGAN R A，et al. Self-assembling organic nanotubes based on a cyclic peptide architecture［J］. Nat， 1993， 366（6453）： 324-327.

DE GROOT N S，PARELLA T，AVILES F X， et al. Ile-phe dipeptide self-assembly： clues to amyloid formation［J］. Biophys J，2007，92（5）：1732-1741.

SAKET A，VIKAS P，VANDANA S. RGD Peptide as a Targeting Moiety for Theranostic Purpose： An Update Study［J］. Int J Pept Res Ther， 2018， 25： 49-65.

BERTRAND N， WU J， XU X， et al. Cancer nanotechnology： The impact of passive and active targeting in the era of modern cancer biology［J］. Adv Drug Delivery Rev， 2014， 66： 2-25.

STONE O A，EL-BROLOSY M，WILHELM K，et al. Loss of pyruvate kinase M2 limits growth and triggers innate immune signaling in endothelial cells［J］. Nat Commun，2018，9（1）：4077.

WANG Z，NIU G，CHEN X. Polymeric materials for theranostic applications.［J］. Pharm Res，2014，31（6）：1358-1376.

HUANG G，KHEMTONG C，BEY E A，et al. Theranostic Polymeric Micelles for Cancer Imaging and Therapy［J］. Nanostruct Sci Technol， 2012， 12： 257-276.

ADAMS M L， LAVASANIFAR A，KWON G S. Amphiphilic block copolymers for drug delivery［J］. J Pharm Sci， 2003， 92（7）： 1343-1355.

MUNTIMADUGU E， KOMMINENI N，KHAN W. Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvir-onment for Cancer Therapy ［J］. Pharmacol Res， 2017， 126： 109-122.

SHI J，KANTOFF P W，WOOSTER R，et al.Cancer nanomedicine： progress， challenges and opportunities［J］. Nat Rev Cancer， 2017， 17（1）： 20-37.

QIN Y，CHEN H，ZHANG Q，et al. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals［J］. Int J Pharm，2011， 420（2）： 304-312.

WAN G Y， CHENG Y Y， SONG J，et al. Nucleus-targeting near-infrared nanoparticles based on TAT peptide-conjugated IR780 for photo-chemotherapy of breast cancer［J］. Chem Eng J， 2020， 380： 122458.

吉垒，张雪豪，杨子欣，等.肿瘤微环境诱导多肽聚合物原位组装行为研究［J］.高分子学报，2019， 50（6）： 642-652.

GUO F， WU J， WU W， et al. PEGylated self-assembled enzyme-responsive nanoparticles for effective targeted therapy against lung tumors［J］. J Nanobiotechnology， 2018， 16（1）： 57.

WANG Y， XUAN J， ZHAO W， et al. Smart and Selective Cancer-Killing Peptides with Cell Penetrating Sequence and Dual-Targeting Mechanism［J］. Colloids Surf， 2019， 586： 124185.

WANG J， LI N， CAO L， et al. DOX-loaded peptide dendritic copolymer nanoparticles for combating multidrug resistance by regulating the lysosomal pathway of apoptosis in breast cancer cells［J］. J Mater Chem B， 2020， 8（6）： 1157-1170.

李若瑾，吴晓雪，王澈. 核定位信号肽修饰的抗肿瘤纳米载药体系［J］. 中国生物化学与分子生物学报，2022， 38（1）： 35-41.

SHI J， LIU S， YU Y， et al. RGD peptide-decorated micelles assembled from polymer-paclitaxel conjugates towards gastric cancer therapy［J］. Colloids Surf B， 2019， 180： 58-67.

GESSNER I， NEUNDORF I. Nanoparticles Modified with Cell-Penetrating Peptides： Conjugation Mechanisms， Physicochemical Properties， and Application in Cancer Diagnosis and Therapy［J］. Int J Mol Sci， 2020， 21（7）： 2536.

SHI X L，ZHU K Y， YE Z D， et al. VCP/p97 targets the nuclear export and degradation of p27Kip1 during G1to S phase transition ［J］. FASEB J， 2020， 34（4）：5 193-5207.

SONG W，SHEN L，WANG Y，et al. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap［J］. Nat Commun， 2018， 9（1）： 2237.

GOODWIN T J，SHEN L，HU M，et al. Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival［J］. Biomaterials， 2017， 141： 260-271.

MOON Y W，HAJJAR J， HWU P，et al. Targeting the indoleamine 2，3-dioxygenase pathway in cancer［J］. J Immunother Cancer， 2015， 3： 51.

LU K，HE C，GUO N，et al. Chlorin-based nanoscale metal-organic framework systemically rejects colorectal cancers via synergistic photodynamic therapy and checkpoint blockade immunotherapy［J］. J Am Chem Soc， 2016， 138（10）： 12502.

KUAI R， OCHYL L J，BAHJAT K S，et al. Designer vaccine nanodiscs for personalized cancer immunotherapy［J］. Nat Mater，2017， 16： 489-496.

ROSS H，BONOMI P，LANGER C，et al. Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex （PPX） in chemonave pts with advanced NSCLC and poor performance status （PS2）［J］. J Clin Oncol， 2006， 24（18 suppl）： 7039-7039.

PAZ-ARES L， ROSS H，O’BRIEN M，et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer［J］. Br J Cancer， 2008， 98（10）： 1608-1613.

HE C， DUAN X，GUO N，et al. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy［J］. Nature Communications， 2016， 7： 12499.

LI C，CAI G，SONG D，et al. Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer［J］. Biomater Sci，2019， 7（9）： 3627-3639.

HAFSI M，PREVERAL S， HOOG C，et al. RGD-functionalized magnetosomes are efficient tumor radioenhancers for X-rays and protons［J］. Nanomedicine， 2020， 23： 102084.

ZHEN Z，TANG W，WANG M，et al. Protein Nanocage Mediated Fibroblast-Activation Protein Targeted Photoimmunotherapy To Enhance Cytotoxic T Cell Infiltration and Tumor Control［J］. Nano Letters， 2017， 17： 862-869.

YAN J，WU Q，ZHAO Z，et al. Light-assisted hierarchical intratumoral penetration and programmed antitumor therapy based on tumor microenvironment （TME）-amendatory and self-adaptive polymeric nanoclusters［J］. Biomaterials， 2020， 255： 120166.

浏览量

490

下载量

CSCD

CNKI被引量

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Tapasin蛋白在肿瘤免疫治疗中的应用及前景

分阶段中药辅助靶向治疗EGFR敏感突变的非小细胞肺癌的临床研究

基于PI3K/AKT信号通路的中药抗肿瘤多药耐药作用研究进展

中药调节信号转导通路诱导肿瘤细胞自噬的实验研究进展

癌因性疲劳学术问题及其动物模型研究述要